Status:
RECRUITING
An Ex-US Study to Assess Treatment Persistence With Risankizumab in Adult Participants With Psoriatic Arthritis
Lead Sponsor:
AbbVie
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18-75 years
Brief Summary
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an ove...
Eligibility Criteria
Inclusion Criteria:
- Participant with a clinical diagnosis of psoriatic arthritis (PsA) with symptom onset at least 6 months prior to the Screening visit and fulfillment of ClASsification for Psoriatic ARthritis (CASPAR) at Baseline visit to confirm that the participant has active disease.
- Participant must have demonstrated an inadequate response to at least 1 Disease-modifying antirheumatic drug (DMARD) (with max 50% Biologic DMARD-Inadequate Response); alternatively, participant must have demonstrated an intolerance to or contraindication for csDMARDs as determined by the investigator.
Exclusion Criteria:
- Participants demonstrated an inadequate response to three or more bDMARDs/targeted synthetic DMARDs (tsDMARDs).
Key Trial Info
Start Date :
January 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2029
Estimated Enrollment :
1200 Patients enrolled
Trial Details
Trial ID
NCT06764693
Start Date
January 31 2025
End Date
February 1 2029
Last Update
February 17 2026
Active Locations (132)
Enter a location and click search to find clinical trials sorted by distance.
1
Cer Instituto Médico /ID# 274445
Quilmes, Buenos Aires, Argentina, 1878
2
Instituto Medico de Alta Complejidad San Isidro S.A. /ID# 274417
San Isidro, Buenos Aires, Argentina, 1642
3
Instituto Médico Río Cuarto /ID# 274421
Río Cuarto, Córdoba Province, Argentina, 5800
4
Landesklinikum Stockerau /ID# 275618
Stockerau, Lower Austria, Austria, 2000